Key facts
- This page summarizes Ehab El-Gabry's Form 4 filing for Akoya Biosciences, Inc. (AKYA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 Feb 2023, 16:02.
Ehab El-Gabry - 23 Feb 2023 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- AKYA
- Reported as of
- 23 Feb 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2023, 16:02:49 UTC
- Prior SEC filing
- 23 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ehab El-Gabry, by Brian McKelligon, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ehab El-Gabry filed Form 4 for Akoya Biosciences, Inc. (AKYA) on 27 Feb 2023.
Change
- Previous filing in this sequence was filed on 23 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKYA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +16,250
- Change %
- Price
- $0.000000
- Shares after
- 16,250
- Date
- 23 Feb 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKYA
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +32,500
- Change %
- Price
- $0.000000
- Shares after
- 32,500
- Date
- 23 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 32,500
- Exercise price
- $12.30
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The restricted stock units shall vest in four (4) equal annual installments beginning on the first anniversary of the grant date and on each anniversary thereafter.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.
Footnote F3
The options shall vest as follows: twenty-five percent (25%) shall vest on the first anniversary of the grant date with the remainder vesting in 36 equal monthly installments beginning on March 23, 2024.